View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
 PRESS RELEASE

NANOBIOTIX Announces Updates to JNJ-1900 (NBTXR3) Clinical Program Fol...

NANOBIOTIX Announces Updates to JNJ-1900 (NBTXR3) Clinical Program Following Transfer of Ongoing Phase 3 Head and Neck Cancer Trial Sponsorship and Operational Control PARIS and CAMBRIDGE, Mass., Oct. 24, 2025 (GLOBE NEWSWIRE) -- (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer and other major diseases, today announced updates to the JNJ-1900 (NBTXR3) clinical development program. Nanobiotix has completed the transfer of NANORAY-312 sponsorship, i...

 PRESS RELEASE

NANOBIOTIX annonce des mises à jour sur le programme clinique de JNJ-1...

NANOBIOTIX annonce des mises à jour sur le programme clinique de JNJ-1900 (NBTXR3) à la suite du transfert de sponsorship et du contrôle opérationnel de l’essai de Phase 3 en cours dans le cancer de la tête et du cou PARIS et CAMBRIDGE, Mass., 24 oct. 2025 (GLOBE NEWSWIRE) -- (Euronext : NANO – NASDAQ : NBTX – la « Société »), société française de biotechnologie en phase de développement clinique avancé, pionnière des approches fondées sur les nanoparticules pour élargir les possibilités de traitement des patients atteints de cancer ou d’autres maladies, annonce aujourd’hui des mises à j...

Jamila El Bougrini ... (+2)
  • Jamila El Bougrini
  • Thibaut Voglimacci-Stephanopoli
 PRESS RELEASE

OSE Immunotherapeutics Reports First Half 2025 Financial Results

OSE Immunotherapeutics Reports First Half 2025 Financial Results OSE Immunotherapeutics Reports First Half 2025 Financial Results NANTES, France, October 15, 2025 – 7:00pm CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), today reported its consolidated financial results for the first half of 2025. The half-year financial statements for 2025 were subject to a limited review by the Company’s statutory auditors and were approved by the Board of Directors on October 15, 2025. 2025 Half-Year Financial Results (IFRS) In million eurosH1 2024H1 2025Revenues69.01.3Other income13....

 PRESS RELEASE

OSE Immunotherapeutics publie ses résultats financiers du 1er semestre...

OSE Immunotherapeutics publie ses résultats financiers du 1er semestre 2025 OSE Immunotherapeutics publie ses résultats financiers du 1er semestre 2025 Nantes, France, le 15 octobre 2025, 19 heures – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), publie aujourd’hui ses résultats financiers consolidés pour le premier semestre 2025. Les états financiers du premier semestre 2025 ont fait l’objet d’une revue limitée par les Commissaires aux Comptes de la Société, et ont été arrêtés le 15 octobre 2025 par le Conseil d’administration. Résultats financiers semestriels 2025 (IFRS) E...

 PRESS RELEASE

Information mensuelle relative au nombre total de droits de vote et d’...

Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social Conformément aux articles L.233-8 II du Code de commerce et 223-16 du Règlement Général de l’Autorité des Marchés Financiers PARIS, 15 oct. 2025 (GLOBE NEWSWIRE) -- Place de cotation : Euronext Paris / NasdaqEuronext Compartiment : B Code ISIN : FR0011341205Nasdaq : NBTXBloomberg : NANO:FPReuters : NANO.PASite web : DateNombre total d’actionscomposant le capitalsocialNombre total de droits de voteTotal théorique1Total exerçable230 septembre 202548 237 47150 318 25750 296 139 À prop...

 PRESS RELEASE

Voting Rights and Shares Capital of the Company

Voting Rights and Shares Capital of the Company In accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers) PARIS, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Market: Euronext Paris / NasdaqEuronext Compartment: B ISIN code: FR0011341205Nasdaq: NBTXBloomberg: NANO:FPReuters: NANO.PAWebsite: DateNumber of SharesOutstandingTotal number of voting rightsTotal voting rights,theoretical1Total voting rights,exercisable2September 30, 202548,237,47150,318,25750,296,139   About NAN...

Jamila El Bougrini ... (+2)
  • Jamila El Bougrini
  • Thibaut Voglimacci-Stephanopoli
 PRESS RELEASE

Appointment of Marc Le Bozec as Interim CEO

Appointment of Marc Le Bozec as Interim CEO Appointment of Marc Le Bozec as Interim CEO Nantes, October 3, 2025, 8:00 a.m. CET – OSE Immunotherapeutics (ISIN: FR0012127173; Mnemonic: OSE) announces the termination of the position as chief executive officer of Mr. Nicolas Poirier and the appointment of Mr. Marc Le Bozec as interim CEO, as decided yesterday by the Board of Directors. The Board of Directors has commenced a formal search for a new permanent Chief Executive Officer. The Board of Directors has empowered Marc Le Bozec to lead a strategic evaluation of OSE's business, with ...

 PRESS RELEASE

Nomination de Marc Le Bozec comme Directeur Général par interim

Nomination de Marc Le Bozec comme Directeur Général par interim Nomination de Marc Le Bozec comme Directeur Général par interim NANTES, France, 3 octobre 2025, 8 heures – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), annonce la cessation des fonctions de M. Nicolas Poirier en tant que Directeur Général, et la nomination de Marc Le Bozec comme Directeur Général par interim, décidées hier par le Conseil d’administration de la Société. Le Conseil d’administration a lancé un processus de recrutement pour identifier un nouveau Directeur Général permanent. Le Conseil d'administra...

 PRESS RELEASE

NANOBIOTIX Announces First Data From Phase 1 Study Evaluating JNJ-1900...

NANOBIOTIX Announces First Data From Phase 1 Study Evaluating JNJ-1900 (NBTXR3) for Patients With Esophageal Cancer Treatment was well-tolerated and injection feasibility was confirmed in 13 patients with locally advanced adenocarcinoma of the esophagus85% (11/13) disease control rate (DCR)69% (9/13) objective response rate (ORR); 6 complete responses and 3 partial responsesRecruitment of 17 additional patients is ongoing as planned Data presented at the 2025 Annual Meeting of the American Society for Radiation Oncology (ASTRO) on October 1st PARIS and CAMBRIDGE, Mass., Oct. 01, 2025 (G...

 PRESS RELEASE

NANOBIOTIX annonce les premières données de Phase 1 évaluant JNJ-1900 ...

NANOBIOTIX annonce les premières données de Phase 1 évaluant JNJ-1900 (NBTXR3) chez des patients atteints de cancer de l’œsophage Le traitement a été bien toléré et la faisabilité de l’injection a été confirmée chez les 13 patients atteints d’adénocarcinome de l’œsophage localement avancé.Le taux de contrôle de la maladie (DCR, disease control rate) était de 85 % (11/13).Le taux de réponse objective (ORR, overall response rate) était de 69 % (9/13) avec 6 réponses complètes et 3 réponses partielles.Le recrutement de 17 patients supplémentaire est en cours. Données présentées le 1 octobre a...

Nicolas David ... (+2)
  • Nicolas David
  • Steven Boumans
APAML APERAM SA
LI KLEPIERRE SA
COV COVIVIO SA
OSE OSE IMMUNOTHERAPEUTICS SA
GFC GECINA SA
NXI NEXITY SA CLASS A
FLY SOCIETE FONCIERE LYONNAISE SA
EXE EXEL INDUSTRIES SA
GYC GRAND CITY PROPERTIES SA
MERY MERCIALYS SA
INEA FONCIERE INEA
WHA WERELDHAVE N.V.
BLND BRITISH LAND COMPANY PLC
MTU MANITOU BF SA
KOF KAUFMAN & BROAD SA
PIG HAULOTTE GROUP SA
ALTA ALTAREA SCA
VNA VONOVIA SE
ACX ACERINOX SA
EBRO EBRO FOODS SA
ELE ENDESA S.A.
XIOR XIOR STUDENT HOUSING N.V.
ICAD ICADE SA
REP REPSOL SA
BYG BIG YELLOW GROUP PLC
COFB COFINIMMO SA
KWS KWS SAAT SE & CO KGAA
COR CORTICEIRA AMORIM SGPS SA
BKT BANKINTER SA
CAI CA IMMOBILIEN ANLAGEN AG
TEG TAG IMMOBILIEN AG
VASTB VASTNED RETAIL BELGIUM NV
PSPN PSP SWISS PROPERTY AG
UBS UBM DEVELOPMENT AG
SPSN SWISS PRIME SITE AG
PAT PATRIZIA AG
MONT MONTEA SCA
AED AEDIFICA SA
CARM CARMILA SAS
LEG LEG IMMOBILIEN AG
CPINV CARE PROPERTY INVEST SA
EDR EDREAMS ODIGEO SA
LOG COMPANIA DE DISTRIBUCION INTEGRAL LOGISTA HOLDINGS S.A.
NVG NAVIGATOR COMPANY SA
ENG ENAGAS SA
A3TV ATRESMEDIA CORPORACION DE MEDIOS DE COMUNICACION SA
MAP MAPFRE SA
SAFE SAFESTORE HOLDINGS PLC
ENC ENCE ENERGIA Y CELULOSA SA
LTA ALTAMIR ACT PORTEUR
ARG ARGAN SA
RENE REDES ENERGETICAS NACIONAIS SA
CABK CAIXABANK SA
ROVI LABORATORIOS FARMACEUTICOS ROVI S.A.
VGP VGP NV
COL INMOBILIARIA COLONIAL SOCIMI SA
DIC DIC ASSET AG
MERLIN MERLIN PROPERTIES SOCIMI S.A.
HBH HORNBACH HOLDING AG & CO. KGAA
DKG DEUTSCHE KONSUM REIT-AG
ALM ALMIRALL SA
SLR SOLARIA ENERGIA Y MEDIO AMBIENTE S.A.
HOME NEINOR HOMES SA
AT1 AROUNDTOWN SA
BFSA BEFESA SA
BBVA BANCO BILBAO VIZCAYA ARGENTARIA S.A.
LAND LAND SECURITIES GROUP PLC
MVC METROVACESA SA
ATRY ATRYS HEALTH
NSI NSI N.V.
CAF CONSTRUCCIONES Y AUXILIAR DE FERROCARRILES S.A.
ULA UNIBAIL-RODAMCO-WESTFIELD SE STAPLED SECS CONS OF 1 SH UNIBAIL RODAMCO + 1 SH WFD UNIB ROD
INS INSTONE REAL ESTATE GROUP AG
AEDAS AEDAS HOMES SA
WDP WAREHOUSES DE PAUW SCA
ECMPA EUROCOMMERCIAL PROPERTIES NV
CTPNV CTP NV
ONE ONE UNITED PROPERTIES SA
SHUR SHURGARD SELF STORAGE LIMITED
FER FERROVIAL SA
ENER GRUPO ECOENER S.A.
HBX HBX GROUP INTERNATIONAL PLC
CIRSA CIRSA ENTERPRISES S.A.
Nicolas David ... (+2)
  • Nicolas David
  • Steven Boumans
APAML APERAM SA
LI KLEPIERRE SA
COV COVIVIO SA
OSE OSE IMMUNOTHERAPEUTICS SA
GFC GECINA SA
NXI NEXITY SA CLASS A
FLY SOCIETE FONCIERE LYONNAISE SA
EXE EXEL INDUSTRIES SA
GYC GRAND CITY PROPERTIES SA
MERY MERCIALYS SA
INEA FONCIERE INEA
WHA WERELDHAVE N.V.
BLND BRITISH LAND COMPANY PLC
MTU MANITOU BF SA
KOF KAUFMAN & BROAD SA
PIG HAULOTTE GROUP SA
ALTA ALTAREA SCA
VNA VONOVIA SE
ACX ACERINOX SA
EBRO EBRO FOODS SA
ELE ENDESA S.A.
XIOR XIOR STUDENT HOUSING N.V.
ICAD ICADE SA
REP REPSOL SA
BYG BIG YELLOW GROUP PLC
COFB COFINIMMO SA
KWS KWS SAAT SE & CO KGAA
COR CORTICEIRA AMORIM SGPS SA
BKT BANKINTER SA
CAI CA IMMOBILIEN ANLAGEN AG
TEG TAG IMMOBILIEN AG
VASTB VASTNED RETAIL BELGIUM NV
PSPN PSP SWISS PROPERTY AG
UBS UBM DEVELOPMENT AG
SPSN SWISS PRIME SITE AG
PAT PATRIZIA AG
MONT MONTEA SCA
AED AEDIFICA SA
CARM CARMILA SAS
LEG LEG IMMOBILIEN AG
CPINV CARE PROPERTY INVEST SA
EDR EDREAMS ODIGEO SA
LOG COMPANIA DE DISTRIBUCION INTEGRAL LOGISTA HOLDINGS S.A.
NVG NAVIGATOR COMPANY SA
ENG ENAGAS SA
A3TV ATRESMEDIA CORPORACION DE MEDIOS DE COMUNICACION SA
MAP MAPFRE SA
SAFE SAFESTORE HOLDINGS PLC
ENC ENCE ENERGIA Y CELULOSA SA
LTA ALTAMIR ACT PORTEUR
ARG ARGAN SA
RENE REDES ENERGETICAS NACIONAIS SA
CABK CAIXABANK SA
ROVI LABORATORIOS FARMACEUTICOS ROVI S.A.
VGP VGP NV
COL INMOBILIARIA COLONIAL SOCIMI SA
DIC DIC ASSET AG
MERLIN MERLIN PROPERTIES SOCIMI S.A.
HBH HORNBACH HOLDING AG & CO. KGAA
DKG DEUTSCHE KONSUM REIT-AG
ALM ALMIRALL SA
SLR SOLARIA ENERGIA Y MEDIO AMBIENTE S.A.
HOME NEINOR HOMES SA
AT1 AROUNDTOWN SA
BFSA BEFESA SA
BBVA BANCO BILBAO VIZCAYA ARGENTARIA S.A.
LAND LAND SECURITIES GROUP PLC
MVC METROVACESA SA
ATRY ATRYS HEALTH
NSI NSI N.V.
CAF CONSTRUCCIONES Y AUXILIAR DE FERROCARRILES S.A.
ULA UNIBAIL-RODAMCO-WESTFIELD SE STAPLED SECS CONS OF 1 SH UNIBAIL RODAMCO + 1 SH WFD UNIB ROD
INS INSTONE REAL ESTATE GROUP AG
AEDAS AEDAS HOMES SA
WDP WAREHOUSES DE PAUW SCA
ECMPA EUROCOMMERCIAL PROPERTIES NV
CTPNV CTP NV
ONE ONE UNITED PROPERTIES SA
SHUR SHURGARD SELF STORAGE LIMITED
FER FERROVIAL SA
ENER GRUPO ECOENER S.A.
HBX HBX GROUP INTERNATIONAL PLC
CIRSA CIRSA ENTERPRISES S.A.
Jamila El Bougrini ... (+2)
  • Jamila El Bougrini
  • Thibaut Voglimacci-Stephanopoli
Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch